Meet your provider Meet your provider either in person or online
These medications (including semaglutide, dulaglutide, and liraglutide) are typically considered when: Metformin and other oral medications have not achieved adequate glycaemic control The patient has a BMI 35 kg/m (or lower thresholds, typically by around 2.5 kg/m, for people of certain ethnic backgrounds including South Asian) Weight loss would benefit other obesity-related comorbidities Insulin therapy is being considered but would have significant occupational implications or weight gain is a concern Continuation criteria apply: for example, treatment should reduce HbA1c by at least 11 mmol/mol (1.0%) and weight by at least 3% at 6 months to be continued
Yes, transitioning between weekly shots and daily oral weight loss medication is clinically possible
More serious but rare complications include pancreatitis, gallbladder disease, and potential thyroid C-cell tumors (observed in rodent studies, with uncertain human relevance)
This exclusive discount is available only to Military.com readers
According to the EY-Parthenon GLP-1 Consumer Survey (March 2025), 44% of users drink less after starting GLP-1 and 82% keep those habits even after stopping treatment
